Moira A Rynn1, John T Walkup2, Scott N Compton3, Dara J Sakolsky4, Joel T Sherrill5, Sa Shen6, Philip C Kendall7, James McCracken8, Anne Marie Albano9, John Piacentini8, Mark A Riddle10, Courtney Keeton10, Bruce Waslick11, Allan Chrisman3, Satish Iyengar4, John S March3, Boris Birmaher4. 1. Columbia University Medical Center (CUMC)/New York State Psychiatric Institute, New York. Electronic address: rynnm@nyspi.columbia.edu. 2. Weill Cornell Medical College and New York Presbyterian Hospital, New York. 3. Duke University Medical Center, Durham, NC. 4. Western Psychiatric Institute and Clinic-University of Pittsburgh Medical Center, Pittsburgh. 5. Division of Services and Intervention Research at the National Institute of Mental Health (NIMH), Bethesda, MD. 6. University of Illinois at Urbana-Champaign. 7. Temple University, Philadelphia. 8. University of California, Los Angeles (UCLA) Semel Institute for Neuroscience and Human Behavior. 9. Columbia University Medical Center (CUMC)/New York State Psychiatric Institute, New York. 10. Johns Hopkins University School of Medicine, Baltimore, MD. 11. Baystate Medical Center, Springfield, MA.
Abstract
OBJECTIVE: To evaluate the frequency of adverse events (AEs) across 4 treatment conditions in the Child/Adolescent Anxiety Multimodal Study (CAMS), and to compare the frequency of AEs between children and adolescents. METHOD:Participants ages 7 to 17 years (mean = 10.7 years) meeting the DSM-IV criteria for 1 or more of the following disorders: separation anxiety disorder, generalized anxiety disorder, or social phobia were randomized (2:2:2:1) to cognitive-behavioral therapy (CBT, n = 139), sertraline (SRT, n = 133), a combination of both (COMB, n = 140), or pill placebo (PBO, n = 76). Data on AEs were collected via a standardized inquiry method plus a self-report Physical Symptom Checklist (PSC). RESULTS: There were no differences between the double-blinded conditions (SRT versus PBO) for total physical and psychiatric AEs or any individual physical or psychiatric AEs. The rates of total physical AEs were greater in the SRT-alone treatment condition when compared to CBT (p < .01) and COMB (p < .01). Moreover, those who received SRT alone reported higher rates of several physical AEs when compared to COMB and CBT. The rate of total psychiatric AEs was higher in children (≤12 years) across all arms (31.7% versus 23.1%, p < .05). Total PSC scores decreased over time, with no significant differences between treatment groups. CONCLUSION: The results support the tolerability/safety of selective serotonin reuptake inhibitor (SSRI) treatment for anxiety disorders even after adjusting for the number of reporting opportunities, leading to no differences in overall rates of AEs. Few differences occurred on specific items. Additional monitoring of psychiatric AEs is recommended in children (≤12 years). Clinical trial registration information-Child and Adolescent Anxiety Disorders (CAMS); http://clinicaltrials.gov; NCT00052078.
RCT Entities:
OBJECTIVE: To evaluate the frequency of adverse events (AEs) across 4 treatment conditions in the Child/Adolescent Anxiety Multimodal Study (CAMS), and to compare the frequency of AEs between children and adolescents. METHOD:Participants ages 7 to 17 years (mean = 10.7 years) meeting the DSM-IV criteria for 1 or more of the following disorders: separation anxiety disorder, generalized anxiety disorder, or social phobia were randomized (2:2:2:1) to cognitive-behavioral therapy (CBT, n = 139), sertraline (SRT, n = 133), a combination of both (COMB, n = 140), or pill placebo (PBO, n = 76). Data on AEs were collected via a standardized inquiry method plus a self-report Physical Symptom Checklist (PSC). RESULTS: There were no differences between the double-blinded conditions (SRT versus PBO) for total physical and psychiatric AEs or any individual physical or psychiatric AEs. The rates of total physical AEs were greater in the SRT-alone treatment condition when compared to CBT (p < .01) and COMB (p < .01). Moreover, those who received SRT alone reported higher rates of several physical AEs when compared to COMB and CBT. The rate of total psychiatric AEs was higher in children (≤12 years) across all arms (31.7% versus 23.1%, p < .05). Total PSC scores decreased over time, with no significant differences between treatment groups. CONCLUSION: The results support the tolerability/safety of selective serotonin reuptake inhibitor (SSRI) treatment for anxiety disorders even after adjusting for the number of reporting opportunities, leading to no differences in overall rates of AEs. Few differences occurred on specific items. Additional monitoring of psychiatric AEs is recommended in children (≤12 years). Clinical trial registration information-Child and Adolescent Anxiety Disorders (CAMS); http://clinicaltrials.gov; NCT00052078.
Authors: Philip C Kendall; Scott N Compton; John T Walkup; Boris Birmaher; Anne Marie Albano; Joel Sherrill; Golda Ginsburg; Moira Rynn; James McCracken; Elizabeth Gosch; Courtney Keeton; Lindsey Bergman; Dara Sakolsky; Cindy Suveg; Satish Iyengar; John March; John Piacentini Journal: J Anxiety Disord Date: 2010-02-06
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: Peter M Wehmeier; Alexander Schacht; Martin Lehmann; Ralf W Dittmann; Susan G Silva; John S March Journal: Child Adolesc Psychiatry Ment Health Date: 2008-05-28 Impact factor: 3.033
Authors: Scott N Compton; John T Walkup; Anne Marie Albano; John C Piacentini; Boris Birmaher; Joel T Sherrill; Golda S Ginsburg; Moira A Rynn; James T McCracken; Bruce D Waslick; Satish Iyengar; Phillip C Kendall; John S March Journal: Child Adolesc Psychiatry Ment Health Date: 2010-01-05 Impact factor: 3.033
Authors: Jerome H Taylor; Eli R Lebowitz; Ewgeni Jakubovski; Catherine G Coughlin; Wendy K Silverman; Michael H Bloch Journal: J Clin Child Adolesc Psychol Date: 2017-09-28
Authors: Nicole E Caporino; Kendra L Read; Nina Shiffrin; Cara Settipani; Philip C Kendall; Scott N Compton; Joel Sherrill; John Piacentini; John Walkup; Golda Ginsburg; Courtney Keeton; Boris Birmaher; Dara Sakolsky; Elizabeth Gosch; Anne M Albano Journal: J Clin Child Adolesc Psychol Date: 2015-10-14
Authors: Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine Journal: Expert Opin Pharmacother Date: 2018-07 Impact factor: 3.889